industry spotlight
BioPharma
Discover the biopharma industry, where data-driven decisions optimize drug development and patient care.
Opening next-generation therapy
Although the biopharma industry is still recovering after a recent economic downturn, the overall market sentiment remains positive. The sector continues to churn out new technologies and therapies, driven by a growing number of aging populations with chronic diseases. Despite a funding dip in 2022-2023, the VC biopharma landscape is optimistic, with signs of an imminent rebound.
Why it matters:
Due to continuously growing market and investor interest startups have more opportunities to capitalize on:
- Extended Reality (XR)
- CRISPR and other gene editing tools
- Nanoparticles to deliver drugs directly to diseased cells
- Telemedicine
Between the lines:
Biopharma startup companies must prepare for high development costs, complex regulations, and the uncertainties of clinical trials.
We’ve helped many biopharma startups, so we do know how to make your business successful and attractive to investors
What we do:
Our expertise lies in securing crucial funding, M&A advisory, and devising exceptional market entry plans and persuasive biopharma pitch decks.
Go deeper:
Explore our biopharma market analysis to learn about its trends and challenges and find key advice on attracting investment.
3x growth
The biopharma market is set for a triple increase by 2032.
8/10
Individuals seek concise information about medications and potential side effects.
50%
Individuals prefer personalized treatments based on their unique genetics.
3/10
Patients are ready to pay more for customized treatments.
$400B
Will be spent on CAM therapies in the USA.
Biopharma Industry Trends 2024
Explore the trends that revolutionize the biopharma industry:
AI in clinical trials: analyzing massive datasets and streamlining drug discovery and development.
Focus on CRISPR for regenerative medicine: editing genes and helping to repair damaged tissues and organs.
Focus on RWD: tracking electronic health records and personalizing therapy.
Telehealth and wearables: tracking patients with chronic conditions for early intervention and better disease management.
Why it matters: сapitalize on biopharma trends to gain market relevance, secure a competitive edge, ensure compliance, and build customer loyalty.
VENTURE LANDSCAPE
Funding for biopharma startups reached $25.10 billion during 2023
Major channels where funds flow:
- CRISPR gene editing
- AI in drug discovery
- Biosimilars
- Delivery technologies
Biopharma industry growth bottlenecks
Explore potential pitfalls for biopharma ventures with detailed breakdowns and effective mitigation strategies.
High costs for production:
Years of R&D, expensive clinical trials, and specialized manufacturing for complex drugs like gene therapies add to a massive financial hurdle for biopharma startups.
Why it matters
High operational costs may lead to:
- Talent shortage
- Delay of product launch and revenue generation
- No scalability
What it takes:
- Utilize cloud computing and AI to streamline research processes
- Collaborate with larger companies for resources and expertise
- Design smaller, more targeted clinical trials
- Implement open-source drug discovery platforms to share research data and resources
Regulatory scrutiny:
Lengthy and complex approval processes can delay life-saving treatments for patients. Growing public pressure to address high drug prices also leads to stricter pricing regulations.
Why it matters
Difficulties with regulations and drug pricing can:
- Stifle innovation and hinder product development
- Lead to delays in reaching profitability
What it takes:
- Collaborate with regulatory agencies and established biopharma companies to streamline the approval process and maintain safety standards
- Explore innovative pricing models like value-based pricing, which ties drug costs to successful treatment outcomes
- Increase transparency in drug pricing and development costs
Funding limitations:
Complex drugs like gene therapies need expensive clinical trials and specialized manufacturing facilities, requiring significant upfront investment.
Why it matters:
Lack of funding means no:
- Growth
- Entering new markets
- Tech advancements
What it takes:
- Present a compelling pitch deck with a practical roadmap for commercial success and realistic financials
- Develop a robust GTM strategy, outline a clear path to market adoption and revenue generation
- Maintain alignment with current healthcare trends
Data security threats:
Biopharma companies hold a wealth of sensitive patient data. Cyberattacks can compromise this data, leading to privacy breaches and reputational damage.
Why it matters:
No robust data security means:
- Loss of patient trust
- Loss of investors confidence
- Regulatory fines
- Potential disruptions to clinical trials
- Limited scalability
What it takes:
- Team up with cybersecurity experts for an audit and pen-testing
- Invest in robust cybersecurity infrastructure
- Implement employee training programs on data security best practices
- Monitor the evolving threat landscape and update security protocols
FAQs
What is biopharma?
Biopharma refers to the pharmaceutical industry that leverages biotechnology to develop drugs. This involves utilizing bacteria, fungi, or plants, to produce specific human proteins or manipulating DNA sequences to achieve therapeutic outcomes.
How to start a biopharma company?
To start a biopharma company, you need to identify a medical need, conduct research and trials, build a skilled team, create a solid business plan, secure funding, develop manufacturing, establish sales and marketing, and invest in long-term growth.
What is the difference between pharma and biopharma?
Pharma uses chemicals for mass-produced drugs, while biopharma leverages living cells for more targeted treatments, often at a higher cost.
How attractive is the industry to potential biopharma investors?
The biopharma industry is a magnet for investors. VCs are eager to support innovative treatments for unmet medical needs, especially in such a rapidly growing market.
If you are a biopharma startup, how easy is it to raise funds today?
While biopharma is a hotbed for investment in 2024, securing funds isn’t a walk in the park. Investors value strong clinical data, a clear value proposition, and a well-defined path to profitability.
How long does it take to create a pitch deck and financial model for a biopharma startup?
We typically finish everything in two to three weeks. However, during busy periods it could stretch to a month. Please reach out to us for more detailed information.
What are the key mistakes in pitch decks in biopharma startups?
The main problem is the absence of an investment story that connects all the slides. Showing only graphs, numbers, and charts isn’t the best way to secure funding. Investors will feel bored and skip to a more appealing project with a persuasive narrative, a solid competitive moat, significant traction, a solid business plan, and a unique value proposition. Thus, ensure you have all this in your deck.
How competitive is the biopharma market?
The biopharmaceutical market is highly competitive, with established players and a plenty of newcomers vying for market share.
What services do you provide for investors looking to invest or already investing in the biopharma sector?
We help investment funds evaluate biopharma projects through comprehensive due diligence, ensuring they back profitable initiatives. Additionally, we roll out full-fledged fundraising support for our partner fund’s associated companies.
Do you provide biopharma startup M&A support?
Absolutely! Whether you need help pinpointing M&A perspectives, creating coherent CIMs, or crafting models for buy-side and sell-side deals, we are always at your service.
Do you make intros to biopharma startup VCs?
Of course! We help link you up with the right venture capitalists in the biopharma space. By assessing your project’s team setup, round size, and product, we’ll make your fundraising journey more successful.
Do you have data or research available to purchase on the biopharma market?
We provide market intelligence for the biopharma industry, featuring industry reports, competitor assessments, and market research. Using data from trusted sources, we help you understand the biopharma landscape, its complexities, and competitive dynamics.
Which growth stage of companies have you worked with in the past?
We support biopharma startups in growth and fundraising from Pre-Seed to Series C and beyond.
Industries we work with
Fuel your next stage of growth with Waveup — your one-stop shop for fundraising support, outsourced M&A advisory, growth strategy consulting, and presentation design. Leave your email, and let's chat!